{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:24:37Z","timestamp":1762521877271,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1053\/j.seminhematol.2016.04.017","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T20:17:45Z","timestamp":1460233065000},"page":"S58-S60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumtic drugs"],"prefix":"10.1053","volume":"53","author":[{"given":"Ulrich A.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2016.04.017_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2010.179","article-title":"Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis","volume":"6","author":"Hoes","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2016.04.017_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar4685","article-title":"The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis","volume":"16","author":"Cutolo","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib4","first-page":"41","article-title":"Night-time glucocorticoid\u2014a paradigm shift in glucocorticoid therapy in rheumatoid arthritis?","volume":"4","author":"Cutolo","year":"2009","journal-title":"Eur Musculoskel Rev"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/ard.56.1.27","article-title":"The timing of glucocorticoid administration in rheumatoid arthritis","volume":"56","author":"Arvidson","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2008.088955","article-title":"Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside","volume":"67","author":"Cutolo","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib7","first-page":"6","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0049-0172(99)80034-1","article-title":"Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis","volume":"29","author":"Kremer","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.37723","article-title":"Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis","volume":"65","author":"Wasko","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >\/=15 mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib15","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"56","author":"van","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib16","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis","volume":"53","author":"Fox","year":"1998","journal-title":"J Rheumatol Suppl"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.60.10.913","article-title":"Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine","volume":"60","author":"Scott","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib21","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib22","first-page":"347","article-title":"Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis","volume":"2","author":"Fleischmann","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib23","first-page":"2201","article-title":"Leflunomide-associated infections in rheumatoid arthritis","volume":"34","author":"Jenks","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","article-title":"Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Kremer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","article-title":"New insights into mechanisms of therapeutic effects of antimalarial agents in SLE","volume":"8","author":"Wallace","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib26","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3899\/jrheum.111616","article-title":"Reconsidering antimalarials in systemic lupus erythematosus: developments of translational clinical interest","volume":"39","author":"Venuturupalli","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib27","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.1780331001","article-title":"The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses","volume":"33","author":"Felson","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(05)78925-X","article-title":"Hydroxychloroquine and retinal safety","volume":"351","author":"Block","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib30","first-page":"150","article-title":"The Canadian Hydroxychloroquine Study Group","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","article-title":"Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort","volume":"61","author":"Pons-Estel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarcon","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2016.04.017_bib33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/art.27300","article-title":"Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort","volume":"62","author":"Shinjo","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:25:27Z","timestamp":1758522327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196316300294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":33,"alternative-id":["S0037196316300294"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.04.017","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumtic drugs","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}